Powerica IPO GMP Today, Date, Price, Reviews & Analysis 2026

The Sai Parenterals IPO is scheduled to open for subscription from March 24 to March 27, 2026, with a price band of ₹372 to ₹392 per share and a face value of ₹5 per equity share. The company aims to raise around ₹409 crore through this book-built issue and is expected to list on the stock exchanges on April 2, 2026.

As of now, the Sai Parenterals IPO GMP (Grey Market Premium) remains around ₹0 / not active, indicating a neutral listing sentiment in the grey market. Investors are closely analyzing the company’s financial performance, pharma sector growth potential, and valuation to assess whether this IPO offers short-term listing gains or long-term investment opportunities.

The most crucial choice by investors would be based on three questions; valuation comfort, financial stability and the probability of listing gains. This informative educational tutorial by Trendy Traders Academy – Best Stock Market Training Institute in India, elaborates on Sai Parenterals IPO Date, Sai Parenterals IPO Price, Sai Parenterals IPO GMP, financial performance, fundamentals, risks, and IPO strategy on simple language with structured data tables.

Sai Parenterals IPO Dates & Timeline

Event	Date
IPO Open Date	24 March 2026
IPO Close Date	27 March 2026
Anchor Investor Bid	23 March 2026
Allotment Finalisation	30 March 2026
Refund Initiation	1 April 2026
Shares Credit	1 April 2026
Listing Date	2 April 2026

About Sai Parenterals Pvt Ltd

The Indian pharmaceutical industry has been one of the most stable industries in the stock markets. Increased healthcare expenditure, export, and hospital infrastructure have provided the pharmaceutical manufacturers with high growth potential in the long run. The proposed Sai Parenterals IPO comes at a time when investors are seriously seeking fundamentally sound businesses and not speculative issues in the market.

Sai parenterals pvt Ltd is a company in pharmaceutical formulations and with great potential in injectable medicines manufacture and contract development services. The company is, in contrast to most new IPO applicants, in a regulated business where operational skills and COR records outweigh expansion stories.

Sai Parenterals IPO Overview

Particulars	Details
IPO Name	Sai Parenterals Pvt Ltd
Issue Type	Book Built Issue
Sai Parenterals IPO Date	March 24-27, 2026
Sai Parenterals IPO Price Band	₹372 to ₹392 per share
IPO Size	₹408.79 Crore
Fresh Issue	₹285 Crore
Offer For Sale	₹123.79 Crore
Face Value	₹5 per share
Listing Exchange	NSE & BSE
Industry	Pharmaceuticals

The IPO combines fresh capital raising and an offer for sale. The extra cash will be raised mainly by the fresh issue funds to finance growth, working capital needs, research and development, and debt optimization.

Sai Parenterals IPO Price Band

Particular	Details
Price Band	₹372 – ₹392 per share
Cut-off Price	₹392
Face Value	₹5
Market Capitalisation (Post Issue)	Approx ₹1,731 Crore

The pricing positions the company within mid-range pharma IPO valuations.

Sai Parenterals IPO Lot Size & Investment

Application Category	Lots	Shares	Investment (₹392)
Retail Minimum	1	38	₹14,896
Retail Maximum	13	494	₹1,93,648
sNII Minimum	14	532	₹2,08,544
bNII Minimum	68	2,584	₹10,12,928

The minimum retail investment stands near ₹15,000, keeping participation accessible for individual investors.

Sai Parenterals IPO Reservation

Category	Allocation
Qualified Institutional Buyers	Up to 50%
Non-Institutional Investors	Minimum 15%
Retail Investors	Minimum 35%

Higher institutional allocation generally improves market confidence during listing.

About Sai Parenterals Pvt Ltd

Sai Parenterals Pvt Ltd is a pharmaceutical formulations company engaged in development and manufacturing of branded generics and contract manufacturing products. The company focuses significantly on sterile injectables, which represent a technically complex and high-compliance segment.

Core operations include:

Injectable formulations manufacturing
Contract Development & Manufacturing Organisation (CDMO) services
Research and formulation development
Domestic and international pharmaceutical distribution

Injectables require advanced sterile facilities, regulatory approvals, and quality assurance systems, creating high entry barriers.

Industry Overview

India ranks among the world’s largest pharmaceutical producers by volume. Growth drivers supporting the sector include:

Rising chronic disease treatment demand
Increasing healthcare penetration
Export opportunities in regulated markets
Government healthcare schemes
Growing hospital infrastructure

Injectables are particularly important in critical care, oncology, and surgical treatments, making demand relatively stable across economic cycles.

Sai Parenterals IPO GMP

Sai Parenterals IPO GMP represents the unofficial trading premium observed before listing. Grey market activity reflects short-term demand sentiment among traders.

Professional IPO traders often follow a structured GMP rule:

If GMP remains greater than 20 percent of IPO price, investors may consider applying primarily for listing gain opportunities.
This rule works because sustained premium levels usually indicate strong subscription demand and positive listing expectations.

However, Grey Market Premium (GMP) is sentiment-based and can change quickly depending on market conditions.

Sai Parenterals Financial Performance

Financials (₹ Crore)	FY23	FY24	FY25
Revenue	97.03	155.18	163.74
EBITDA	17.86	33.08	40.02
Profit After Tax	4.38	8.41	14.45
Total Assets	133.96	268.10	272.39

Key observations:

Revenue growth shows strong operational expansion.
Profitability has improved consistently.
EBITDA growth indicates better operating efficiency.

Fundamental Analysis

Strengths in terms of business model: Sai Parenterals is a controlled pharmaceutical industry that involves certifications of compliance, and production skills. New competition is deterred in such industries.
Revenue Increase: Revenue almost doubled between the FY23 and FY25 implying scaling capabilities and enhanced order processing.
Profitability Improvement: Profit after tax has improved over three times in two years and this shows a better leverage of operations.
Balance Sheet Position: IPO proceeds could be used to optimize debt and enhance financial flexibility as well as lower interest coverage.

IPO Valuation Analysis

Metric	Value
PE Ratio	111x
Market Cap	₹1,731 Crore
Sector	Pharma Formulations

The valuation appears premium compared to traditional pharma companies, meaning growth expectations are already partially priced in.

Strengths of Sai Parenterals IPO

Established pharmaceutical manufacturing capabilities
Presence in injectable segment with higher margins
Improving financial performance
Expansion and R&D investment plans
Experienced management team

Risks Investors Should Know

High valuation relative to earnings
Regulatory compliance risks
Dependence on approvals and audits
SME-style volatility despite mainboard listing
Client concentration risk

Should You Apply for Sai Parenterals IPO

For Listing Gains

One may consider applying if:

GMP sustains above 20 percent
QIB subscription remains strong
Overall market sentiment is stable

For Long-Term Investment

Suitable for investors who believe in:

Pharma manufacturing growth
Export expansion opportunities
Long-term healthcare demand trends

IPO Strategy Framework for Beginners

Many investors apply blindly during IPO hype cycles. A disciplined process improves outcomes.

Step 1: Study company fundamentals
Step 2: Compare valuation with peers
Step 3: Track GMP trend consistency
Step 4: Monitor subscription demand
Step 5: Decide clear investment objective

IPO investing should be data-driven rather than emotion-driven.

From an educational perspective, Sai Parenterals represents a fundamentally improving pharmaceutical business with visible revenue growth. The injectable segment adds structural strength, but valuation remains an important factor.

This IPO may attract both traders seeking listing gains and investors looking for healthcare exposure. Decision-making should combine GMP analysis, subscription demand, and financial evaluation rather than relying on market hype.

Conclusion

The Sai Parenterals IPO is an introduction of a growing pharmaceutical formulations company to the public markets at the time when the demand of health care is steadily growing across the globe. At a price range of 372-392, lot size of 38 shares and minimum investment of less than 15,000, the IPO is affordable to the retail investors.

Good growth in revenue and profitability improvement give a solid backing to the basic story of the company, but valuation at a premium should be taken into account. The investor must watch the trends of Sai Parenterals IPO GMP and institutional involvement carefully and then apply.

One of the rules that many experienced traders have lived by is to think about taking an IPO when GMP has been above 20 percent. That means the listing sentiment is stronger. Nevertheless, IPO investments are risky enough and there is no better investment advantage than knowledgeable analysis.

Disclaimer

This article is for educational purposes only and should not be considered financial advice. IPO investments are subject to market risks. Investors should read the Red Herring Prospectus (RHP) and consult a financial advisor before making investment decisions. Trendy Traders Academy is not responsible for any financial losses.

Also Read : Amir Chand Jagdish Kumar IPO GMP, Date, Price, Analysis 2026